Thank you, Scott. At the close of the market today we issued a press release announcing our operating and financial results for the third quarter of 2019. Our summary financial results are shown here, and I will review them now in more detail. Our GAAP net loss for the 3 months ended September 30, 2019 was $3.1 million compared to a net loss of $3.4 million in the third quarter of 2018. Our lower net loss was primarily due to a $254,000 increase in revenue and lower operating expenses, which were $3.2 million in the third quarter of this year as compared to $3.5 million in the third quarter of 2018. Revenue of $254,000 consisted of $222,000 of engineering services revenue and $32,000 of license revenue In Q3, we did not have any revenue and in Q2 2019 we had $70,000 of revenue. Gross margin of 20% in Q3 compared to 70% in Q2 due to much higher mix of engineering services this quarter. On a per share basis, our GAAP net loss in Q3 2019 was $0.19 per share, down from a loss of $0.28 per share in Q3 2018. This decline reflects a lower net loss, as well as an increase in weighted average shares outstanding to $16.6 million in Q3 2019 from 12.1 million shares in Q3 2018. Our press release and this slide contain reconciliation between our GAAP and non-GAAP results. As you can see the major difference between our GAAP and non-GAAP results is stock-based compensation expense, which is a non-cash item. Our stock compensation expense in Q3 2019 was $798,000 as compared to $630,000 in Q3, 2018. Non-GAAP adjusted EBITDA in the third quarter was a loss of $2.4 million compared to a loss of $2.8 million in Q3 2018 reflecting the same factors that affected our GAAP results. I will now go into more detail on the components of our operating expenses. R&D expenses in Q3 2019 were $1.7 million, a decrease of approximately $176,000 from $1.9 million in Q3 2018, which reflected both a decline of outsourced fabrication and test expenses as well as an allocation of more of our R&D expense to cost of revenue from engineering services as that was a higher mix of our revenue. Our G&A expenses in Q3 2019 were $1.2 million, a decline of $85,000 from Q3 2018 G&A expenses of $1.3 million. This decline reflected lower professional fees and payroll costs. Offset in part by higher non-cash compensated expense. Looking at our results on a sequential quarterly basis, third quarter 2019 GAAP net loss was $3.1 million compared to a net loss of $3.6 million in the second quarter. GAAP net loss per share in Q3 declined to $0.19 per share, from $0.24 per share in Q2 reflecting the note lower net loss, as well as the increase in weighted average shares outstanding as our most recent equity financing closed on May 30 2019. So those shares were only outstanding for one month of Q2. Non-GAAP adjusted EBITDA loss declined $2.4 million in Q3 from a loss of $2.9 million in Q2. This decline was primarily due to lower R&D expenses in Q3 due to a surge in outsourced fabrication and test expenses in the first half of this year related to the development of our MST SP technology for the analog market. Although we do not expect Q4 R&D expenses to revert to the level of the second quarter we do expect to see gradual increases in R&D expense continuing into next year as we add more capacity for epitaxial deposition and growing customer support. G&A expenses were also down sequentially, principally due to the timing of professional fees. Turning to the balance sheet, our cash at September 30 2019 was $16.8 million, down $2.3 million from our $19.1 million cash balance at June 30 2019. Our Q2 cash consumption was $2.4 million exclusive of the proceeds of our May 2019 financing. We are reiterating the full-year 2019 guidance that cash consumption as well as non-GAAP operating expenses will be in the range of $11.5 to $12.5 million. On previous earnings calls, I talked about our plans to lease an additional Epi tool to use for both customer wafers and internal R&D. We have now reached agreement to lease, a new tool and during Q4, we will be making a deposit of $450,000, which obviously will impact our cash balance. Lease payments will not hit our income statement. Until the new tool is accepted, which we expect will happen in the first quarter of next year. As Scott mentioned, we just executed an integration license agreement with a fabless vendor and we will recognize revenue from this vendor in Q4. This is probably a good time to review how we recognize revenue from license agreements. Under ASC 606, the most important factor for timing of revenue recognition is when our performance obligations have been met. Because our integration license agreements, provide that Atomera will do the MST deposition on our customers' wafers revenue recognition from those contracts depends on both when we signed the contract which confers rights to work on our MST technology as well as on when we deliver the wafers. Our arrangements with integration license customers generally also require payments for the engineering service work. So wafer runs for a licensee can give rise to both types of revenue. Based on our recent license signings the associated engineering service work and our other customer engagements, we currently anticipate that our Q4 revenue will be in the range of $125,000 to $150,000. We continue to see momentum in paid engagements for engineering services, resulting from our breakthrough and 5-volt analog, RF SOI and FinFET. And we are also in discussions with multiple customers about licenses, but our visibility remains our visibility on timing of those licenses and engineering services remains limited. With that I will turn the call back to Scott for a few summary remarks before we open the call up to questions. Scott.